ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Brain Diseases
Nervous System Diseases
Neurocognitive Disorders

Alzheimer's Disease trials near New Haven, CT, USA:

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...

Enrolling
Early Alzheimer's Disease
Drug: Placebo
Drug: CT1812

Phase 2

Cognition Therapeutics
Cognition Therapeutics

New Haven, Connecticut, United States and 14 other locations

A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's ...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: BMS-984923

Phase 1

Allyx Therapeutics

New Haven, Connecticut, United States and 1 other location

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

Phase 3

Lilly
Lilly

New Haven, Connecticut, United States and 75 other locations

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Solanezumab
Drug: Lecanemab

Phase 2, Phase 3

The Washington University
The Washington University

New Haven, Connecticut, United States and 38 other locations

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Lecanemab
Drug: E2814

Phase 2, Phase 3

The Washington University
The Washington University

New Haven, Connecticut, United States and 37 other locations

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

New Haven, Connecticut, United States and 111 other locations

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: LY3372689
Drug: Placebo

Phase 2

Lilly
Lilly

New Haven, Connecticut, United States and 68 other locations

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elder...

Active, not recruiting
Alzheimer's Disease (AD)
Drug: Placebo for ABBV-552
Drug: ABBV-552

Phase 2

AbbVie
AbbVie

Stamford, Connecticut, United States of America and 63 other locations

versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Other: Placebo
Biological: Bepranemab

Phase 2

UCB
UCB

New Haven, Connecticut, United States and 101 other locations

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting
Alzheimer's Disease
Drug: Lecanemab 2.5 mg/kg
Drug: Lecanemab 10 mg/kg

Phase 2

Eisai
Eisai

New Haven, Connecticut, United States and 168 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems